Nano-X Imaging (NNOX)

A Complete Farce on the Market – Theranos 2.0

$0 Price Target

Since its recent IPO, Nano-X Imaging (NNOX) has become a market darling based on the claim that they have created a better medical imaging device that is low cost, portable, and will forever change the way diagnostics are done globally as this new innovative technology will soon replace the legacy x-ray market.

Citron puts NNOX under a corporate x-ray and we see right through it as a stock promotion that is actually insulting to anyone who spends 10 minutes to read the prospectus. This stock is heading to $0 as the company’s recent fair value opinion on their technology is $0.14 a share.